Our technology

NemaGen's recent breakthrough has identified a requirement for the metabolic enzyme, carbonic anhydrase 1 (Car1) in mast cell development. We are advancing these findings by developing novel chemical compounds that target Car1 and prevent mast cell-mediated inflammation. This innovative program seeks to develop much needed treatments for allergic inflammation, mastocytosis, and other mast cell-related diseases. NemaGen currently has an oral preclinical lead stage candidate that meets efficacy and safety criteria. 

  NemaGen is also developing a first-in-class therapeutic that targets carbonic anhydrase 4 (Car4). Car4 is a lineage defining cell surface marker of alveolar macrophages. Importantly, NemaGen has identified that Car4 deficiency leads to spontaneous emphysema and fibrosis. Additionally, NemaGen has demonstrated that Car4 treatment protects against lung damage in murine models of emphysema. Notably, Car4 is amongst the highest down-regulated proteins in COPD patients presenting with emphysema, and is highly downregulated in patients with idiopathic pulmonary fibrosis (IPF). NemaGen is leveraging these novel findings and developing a novel Car4-derived therapeutic to treat pulmonary inflammation for patients with COPD, emphysema, and IPF. 

NemaGen's cutting-edge neuroimmunology studies have revealed that the neuropeptide, neuromedin B (NMB), is a potent inhibitor of lung inflammation. Lung diseases including COPD represent the leading cause of death and disability worldwide and novel therapeutics are desperately needed.  This program is advancing NMB delivery strategies to treat both acute and chronic inflammatory responses in the lung.